OrganogenesisOrganogenesis (NSDQ:ORGO) posted second-quarter results this week that beat the overall consensus on Wall Street.

The Canton, Mass.-based company reported profits of $20.7 million, or 15¢ per share, on sales of $123.2 million for the three months ended June 30 for a sales growth of 78.65% compared with Q2 2020.

Earnings per share were 15¢, 8¢ ahead of The Street, where analysts were looking for sales of $107.3 million.

“The Organogenesis team executed extremely well in the second quarter, further accelerating our growth momentum,” president and CEO Gary Gillheeney said in a news release. “We delivered 79% year-over-year revenue growth with strong contributions across both our advanced wound care and surgical and sports medicine portfolios as well as significantly improved profitability.”

“As we enter the second half of 2021, we remain focused on executing our commercial strategy and believe we are well-positioned to continue to deliver strong operating and financial results. Given the deep dedication to the patients we serve, we remain confident in our ability to provide integrated healing solutions that substantially improve medical outcomes while lowering the overall cost of care.”

Organogenesis said it expects full-year 2021 revenue to be in the range of $456 million and $472 million to represent a 35% to 40% year-over-year growth.

Shares in ORGO were up 14.84% to $17.02 apiece in pre-market trading.